Novel |
ELK4 |
ETS transcription factor ELK4 |
|
|
|
Novel |
MDM2 |
MDM2 proto-oncogene |
- AKT phosphorylates targets in the cytosol
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- Trafficking of AMPA receptors
- Constitutive Signaling by AKT1 E17K in Cancer
- Ub-specific processing proteases
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Methylation
- Stabilization of p53
- Regulation of RUNX3 expression and activity
|
- Zinc
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Choriocarcinoma
- Osteosarcoma
- Glioma
- Penile cancer
- Alveolar rhabdomyosarcoma
|
Novel |
MGMT |
O-6-methylguanine-DNA methyltransferase |
- MGMT-mediated DNA damage reversal
|
- Cysteine
- Zinc
- S-Methylcysteine
- S-Benzylcysteine
- Dinitrochlorobenzene
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
Novel |
OAT |
ornithine aminotransferase |
- Glutamate and glutamine metabolism
|
- Pyridoxal phosphate
- Ornithine
- Gabaculine
- Canaline
|
|
Novel |
PLSCR1 |
phospholipid scramblase 1 |
|
|
|
Novel |
PLXNA1 |
plexin A1 |
- Sema3A PAK dependent Axon repulsion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- CRMPs in Sema3A signaling
- Other semaphorin interactions
|
|
|
Novel |
PTPRE |
protein tyrosine phosphatase receptor type E |
|
- Alendronic acid
- Tiludronic acid
|
|
Novel |
SEC23IP |
SEC23 interacting protein |
- COPII-mediated vesicle transport
|
|
|
|
ANOS1 |
anosmin 1 |
- FGFR1c ligand binding and activation
- Negative regulation of FGFR1 signaling
|
|
- Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
|
|
APP |
amyloid beta precursor protein |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Tromethamine
- Phenserine
- Tetrathiomolybdate
- CAD106
- Mito-4509
- Edonerpic
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
- Zinc acetate
- Aluminium phosphate
- Aluminum acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
BEX1 |
brain expressed X-linked 1 |
|
|
|
|
BEX2 |
brain expressed X-linked 2 |
|
|
|
|
CACNA1D |
calcium voltage-gated channel subunit alpha1 D |
- Adrenaline,noradrenaline inhibits insulin secretion
- NCAM1 interactions
- Regulation of insulin secretion
- Regulation of insulin secretion
|
- Ergocalciferol
- Enflurane
- Ranolazine
- Phenytoin
- Isradipine
- Topiramate
- Nimodipine
- Nisoldipine
- Spironolactone
- Cinnarizine
- Nicardipine
- Magnesium sulfate
- Levomenthol
- Ethanol
- Felodipine
- Nitrendipine
- Miconazole
- Nifedipine
- Amiodarone
- Mibefradil
- Dronedarone
- Clevidipine
- Nilvadipine
- Trimebutine
- Aranidipine
- Benidipine
- Cilnidipine
- Lacidipine
- Levamlodipine
- Manidipine
- Butamben
- Bioallethrin
- Bioallethrin
- Fish oil
|
|
|
CTDSP1 |
CTD small phosphatase 1 |
|
- Aspartate beryllium trifluoride
- Citric acid
|
|
|
CTDSPL |
CTD small phosphatase like |
|
|
|
|
DUSP14 |
dual specificity phosphatase 14 |
|
|
|
|
EPHA4 |
EPH receptor A4 |
- EPH-Ephrin signaling
- EPH-Ephrin signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- EPH-ephrin mediated repulsion of cells
|
|
|
|
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
- Signaling by ERBB2
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Downregulation of ERBB2:ERBB3 signaling
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D induced cell migration and growth-cone collapse
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Trastuzumab
- Lapatinib
- IGN311
- Trastuzumab emtansine
- Varlitinib
- AV-412
- Pertuzumab
- Afatinib
- Tucatinib
- Tesevatinib
- Fostamatinib
- Brigatinib
- Margetuximab
- Zanubrutinib
|
- Choriocarcinoma
- Pancreatic cancer
- Gastric cancer
- Bladder cancer
- Endometrial Cancer
- Ovarian cancer
- Cholangiocarcinoma
- Breast cancer
- Cervical cancer
|
|
ERRFI1 |
ERBB receptor feedback inhibitor 1 |
|
|
|
|
FBXO7 |
F-box protein 7 |
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|